Cargando…
Induction of apoptosis by HBI‐8000 in adult T‐cell leukemia/lymphoma is associated with activation of Bim and NLRP3
Adult T‐cell leukemia/lymphoma (ATL) is an aggressive T‐cell malignancy caused by human T‐cell lymphotropic virus 1. Treatment options for acute ATL patients include chemotherapy, stem cell transplantation, and recently the anti‐chemokine (C‐C motif) receptor 4 antibody, although most patients still...
Autores principales: | Hasegawa, Hiroo, Bissonnette, Reid P., Gillings, Mireille, Sasaki, Daisuke, Taniguchi, Hiroaki, Kitanosono, Hideaki, Tsuruda, Kazuto, Kosai, Kousuke, Uno, Naoki, Morinaga, Yoshitomo, Imaizumi, Yoshitaka, Miyazaki, Yasushi, Yanagihara, Katsunori |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982578/ https://www.ncbi.nlm.nih.gov/pubmed/27193821 http://dx.doi.org/10.1111/cas.12971 |
Ejemplares similares
-
The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors
por: Bissonnette, Reid P., et al.
Publicado: (2021) -
HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors
por: Shojaei, Farbod, et al.
Publicado: (2022) -
Oral histone deacetylase inhibitor tucidinostat (HBI‐8000) in patients with relapsed or refractory adult T‐cell leukemia/lymphoma: Phase IIb results
por: Utsunomiya, Atae, et al.
Publicado: (2022) -
Oral histone deacetylase inhibitor HBI-8000 (tucidinostat) in Japanese patients with relapsed or refractory non-Hodgkin’s lymphoma: phase I safety and efficacy
por: Yoshimitsu, Makoto, et al.
Publicado: (2022) -
Risk Factors for Acquisition of Fluoroquinolone or Aminoglycoside Resistance in Addition to Carbapenem Resistance in Pseudomonas aeruginosa
por: Kosai, Kosuke, et al.
Publicado: (2018)